Literature DB >> 10706079

A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice.

S E Blutt1, T C Polek, L V Stewart, M W Kattan, N L Weigel.   

Abstract

Limited options for the treatment of prostate cancer have spurred the search for new therapies. One innovative approach is the use of 1alpha,25-dihydroxyvitamin D3 (calcitriol) analogues to inhibit cancer growth. We demonstrate here that the calcitriol analogue, EB1089, extensively inhibits the growth of LNCaP prostate cancer cells in culture and causes the cells to both accumulate in G0-G1 and undergo apoptosis. Importantly, we found that EB1089 inhibits the growth of LNCaP tumor xenografts in nude mice. Because of these antiproliferative properties in vivo, EB1089 is a potential new therapeutic agent for the treatment of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10706079

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  24 in total

1.  Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells.

Authors:  Yong Xu; Fang Fang; Daret K St Clair; Sajni Josson; Pradoldej Sompol; Ivan Spasojevic; William H St Clair
Journal:  Mol Cancer Ther       Date:  2007-06-29       Impact factor: 6.261

2.  Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status.

Authors:  Sarah Mordan-McCombs; Theodore Brown; Wei-Lin Winnie Wang; Ann-Christin Gaupel; Joellen Welsh; Martin Tenniswood
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-27       Impact factor: 4.292

3.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

4.  The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.

Authors:  Jung-Sun Kim; Justin M Roberts; William E Bingman; Longjiang Shao; Jianghua Wang; Michael M Ittmann; Nancy L Weigel
Journal:  Endocrinology       Date:  2014-06-13       Impact factor: 4.736

5.  Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer.

Authors:  Srilatha Swami; Aruna V Krishnan; Jennifer Y Wang; Kristin Jensen; Ronald Horst; Megan A Albertelli; David Feldman
Journal:  Endocrinology       Date:  2012-03-27       Impact factor: 4.736

6.  The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.

Authors:  Zheng Shen; Xiaohui Zhang; Jinfu Tang; Ravi Kasiappan; Umesh Jinwal; Pengfei Li; Shan Hann; Santo V Nicosia; Jie Wu; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Cell Endocrinol       Date:  2011-03-30       Impact factor: 4.102

Review 7.  Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.

Authors:  Panida Lungchukiet; Yuefeng Sun; Ravi Kasiappan; Waise Quarni; Santo V Nicosia; Xiaohong Zhang; Wenlong Bai
Journal:  J Steroid Biochem Mol Biol       Date:  2014-11-06       Impact factor: 4.292

8.  New paradigms for advanced prostate cancer.

Authors:  Daniel P Petrylak
Journal:  Rev Urol       Date:  2007

Review 9.  Vitamin D, the renin-angiotensin system, and insulin resistance.

Authors:  George Rammos; Paraskevi Tseke; Stavroula Ziakka
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

10.  EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.

Authors:  Vandanajay Bhatia; Manjit K Saini; Xiaoli Shen; Lian X Bi; Suimin Qiu; Nancy L Weigel; Miriam Falzon
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.